Subscribe
Share
Share
Embed
This episode takes the patients who arrive after a structural and reflux workup has already come back clean. Here the history leads and the test only confirms, so the whole skill is recognizing the phenotype on the story. PPI failure in someone who looks like GERD on the surface is the alert that the diagnosis is not GERD.
The case. A young woman regurgitates recognizable food ten to fifteen minutes after nearly every meal. It is effortless, without nausea or retching, and she has gained weight on twice-daily PPI. What is the diagnosis, what test confirms it, and why is more acid suppression the wrong move?
Topics covered
Key decisions
For the full chapter with MCQs, tables, and primary-guideline references, visit www.boardpearls.com.
Questions or feedback: hello@boardpearls.com.
Board Pearls is a gastroenterology board review built around clinical reasoning, not recall. Each episode takes one high-yield topic and works it the way you would on rounds: a case to anchor it, the framework that sorts the differential, and the specific decisions the exam rewards.
The gastroenterology series covers the full blueprint across nine modules: esophagus, stomach and duodenum, small bowel, colon, pelvic floor, liver, pancreas and biliary, endoscopy, and the cross-cutting topics. Episodes are grouped by chapter and built from the primary guidelines and pivotal trials the boards draw from (ACG, AGA, AASLD, ASGE), not from textbook summaries.
Use it as an audio companion to the written curriculum, MCQs, and AI tutor at boardpearls.com. Questions or feedback: hello@boardpearls.com.
Welcome to Board Pearls. This is episode two of three of the Esophageal Symptoms and Diagnostic Workup chapter, in the Esophageal Disorders module. In this episode we cover the esophageal symptoms that are not classic dysphagia: globus and rumination and the functional pain syndromes, and odynophagia sorted by exposure history. The post-surgical and systemic dysphagias that the standard workup misses come in episode three.
The patients in this episode share a clinical predicament. They arrive in clinic after a structural and reflux workup has already come back clean. The work is to recognize the phenotype on the history alone, because in this set the test does not lead the diagnosis. The history leads, and the test confirms.
Start with globus. A patient describes a persistent lump or tightness in the throat between meals. The sensation is there when she is not eating, and it actually eases or stays the same when she swallows water or food, rather than getting worse. That is the recognition pattern, and it is the inverse of true dysphagia. True dysphagia worsens with the swallow because the bolus has nowhere to go. Globus is unchanged or improved by the swallow because the sensation is a heightened perception of normal pharyngeal sensation, not an obstructing lesion. The mechanism is multifactorial. Hypertonic upper esophageal sphincter behavior, post-nasal drip, and reflux-related laryngeal sensitization each contribute in a subset of patients, but in most no single physiologic abnormality is found. The workup is therefore targeted rather than exhaustive. Screen for reflux and post-nasal drip with history and a focused exam. Look for a structural lesion only when alarm features are present: true dysphagia, weight loss, hoarseness, a neck mass, or a smoking history. An ENT exam excludes the organic lesions at the level of the larynx and hypopharynx that mimic the sensation. Once the alarm screen is negative, reassurance is part of management, not a placeholder for it. The natural history is benign, and escalation rarely improves the outcome. A PPI is not a default answer for globus, because the lesion is not acid.
Rumination syndrome is the diagnosis that looks like GERD on the surface and fails twice-daily PPI for a reason. A young patient describes food coming back up after nearly every meal. The episodes begin ten to fifteen minutes after she eats. They are effortless. They are not preceded by nausea or by retching. She chews the regurgitated material and either re-swallows it or spits it out, and the material is recognizable as the food she just ate. She has been on a high-dose PPI without improvement, and she has often gained weight rather than lost it. That is the clinical fingerprint. The mechanism is a learned, unintentional contraction of the abdominal wall and the diaphragm that raises intra-abdominal pressure against a relaxed lower esophageal sphincter. The pressure drives undigested gastric contents back up into the esophagus and the pharynx. The Rome four criteria require effortless regurgitation of recently swallowed food on most days for at least three months, with onset at least six months earlier, without antecedent retching. The diagnostic test that nails it is high-resolution manometry with concurrent impedance during a postprandial study. The fingerprint is the abdominal-strain R-wave: a simultaneous rise in intragastric and intra-esophageal pressure in the postprandial window, often with the lower esophageal sphincter relaxing at the same instant. That pattern is not GERD and it is not vomiting. The trap here is to keep escalating acid suppression because the patient is regurgitating after meals. The diagnosis is behavioral, and acid suppression has no role. Treatment is diaphragmatic breathing taught by behavioral therapy. Slow deep abdominal inspiration during the postprandial window is physically incompatible with the abdominal wall contraction that drives the rumination event, which is why the technique works. Cognitive behavioral therapy is added for refractory cases. Fundoplication is not the answer either, because the mechanism is not a failed antireflux barrier.
Supragastric belching sits in the same behavioral family. Air is sucked into the esophagus and then immediately expelled, in a learned cycle that occurs in the awake patient and disappears during sleep or during conversation that requires the same oropharyngeal apparatus. It is recognized on the history and on impedance, and it responds to the same kind of diaphragmatic-breathing retraining that helps rumination.
Functional chest pain is noncardiac chest pain after cardiac disease, GERD, eosinophilic esophagitis, and primary motility disorders have all been excluded by appropriate testing. The mechanism is visceral hypersensitivity at the level of the esophageal afferent neurons and the central pain processing pathways. Non-painful esophageal events such as low-volume reflux or normal contractions or mild distension are perceived as pain because the gain on the pathway is set too high. The careful reading that misleads here is to reach for a higher PPI dose when a standard dose has failed, because the symptom sounds reflux-shaped. That move is wrong. The lesion is in the pain processing pathway, not in the acid burden, which is why the answer is a neuromodulator rather than more acid suppression. A low-dose tricyclic such as imipramine at twenty-five to fifty milligrams at bedtime, or amitriptyline at the same dose, is first line. An SSRI is a tolerability alternative. Hypnotherapy and cognitive behavioral therapy each have evidence and each are reasonable choices in patients who prefer a non-pharmacologic approach. The neuromodulator is the first-line drug class. Not a higher PPI dose.
Functional heartburn and reflux hypersensitivity are the brain-gut-axis diagnoses on the heartburn side, and they are detailed in the GERD chapter. The short version belongs here because the recognition pattern is the same. Functional heartburn is heartburn with normal acid exposure time and a negative symptom-reflux association, and it is treated with a neuromodulator. Reflux hypersensitivity is heartburn with normal acid exposure time but a positive symptom-reflux association. It is treated with combined neuromodulator and acid suppression. The patient genuinely associates symptoms with physiologic reflux events, but the volume of acid exposure is below the threshold that defines GERD. The Lyon Consensus framework that separates these patients from true GERD is covered in chapter three.
Now to odynophagia. The principle is that pain with swallowing is mucosal injury until proven otherwise, and the differential is sorted by exposure history before a single test is ordered. Three exposure axes do the work. The pill axis asks whether a tablet was swallowed with too little water or in a recumbent position. The immune-status axis asks about HIV CD4 count, transplant status, chemotherapy, and chronic inhaled or systemic steroids. The prior-injury axis asks about deep reflux or caustic ingestion. Pinning the exposure narrows the differential to one or two diagnoses before EGD, and the EGD is then directed toward biopsy of the appropriate site. Caustic ingestion is named here and covered in detail in the GI emergencies chapter.
Pill esophagitis is direct mucosal injury at the point of pill contact. A pill lodges in two predictable places. The first is the level of the aortic arch, where the left mainstem bronchus indents the esophagus. The second is the lower esophageal sphincter, where a slow propagated wave can leave a pill in contact with the wall for minutes. The mechanism is local toxicity from the dissolved tablet contents. The pH of the dissolved drug, its osmolality, and its tissue contact time each contribute. The offenders are doxycycline and tetracycline, potassium chloride (especially extended-release formulations), bisphosphonates such as alendronate and risedronate, NSAIDs and aspirin, iron, clindamycin, ascorbic acid, quinine and quinidine, and dabigatran. The risk factors are taking a pill with little or no water, recumbent dosing, or an underlying motility disorder or stricture that prolongs contact time. The classic vignette is sudden retrosternal odynophagia hours to days after a specific pill, often in a young patient who took doxycycline for acne at bedtime with a small sip of water. EGD shows discrete, often shallow ulcers at the aortic arch level with normal intervening mucosa, and the kissing pattern of paired ulcers on opposing walls is the giveaway. Histology shows ulceration with neutrophilic and reactive epithelial inflammation, without the eosinophilic infiltrate of eosinophilic esophagitis and without the viral inclusions of HSV or CMV. Treatment is removal of the offending agent, a sucralfate slurry to coat the injured mucosa, and swallowing-technique counseling: take pills upright with at least eight ounces of water and remain upright for thirty minutes. A brief PPI course is added when reflux is concurrent. Symptoms typically resolve within one to two weeks.
Infectious esophagitis sorts by host immune status, and the host narrows the differential before EGD. Candida is the most common. The host pattern is the PPI user on inhaled corticosteroids, the HIV patient with a CD4 count under two hundred, and the solid-organ or stem-cell transplant recipient. It is also the patient on long-term broad-spectrum antibiotics, and the patient with esophageal stasis from achalasia or stricture. The mechanism is overgrowth of normal oral and esophageal Candida flora when local mucosal defense fails. Endoscopy shows white or yellow-white plaques adherent to the mucosa, typically diffuse, that do not wash off with irrigation. Brushings or biopsies show pseudohyphae and yeast forms. Treatment is fluconazole at two hundred to four hundred milligrams daily for fourteen to twenty-one days. An echinocandin is used when fluconazole resistance is documented or strongly suspected, particularly in transplant recipients with prior azole exposure.
HSV esophagitis is recognized by shallow ulcers with raised, well-demarcated edges, often described as volcano-edge ulcers, distributed in the mid to distal esophagus. The histologic fingerprint is multinucleated giant cells with intranuclear Cowdry type A inclusions in the squamous epithelial cells at the edge of the ulcer. That location matters at the moment of biopsy. HSV biopsies are taken from the ulcer edge, because that is where the infected epithelial cells live. Treatment is acyclovir at four hundred milligrams orally five times daily for fourteen to twenty-one days in the immunocompromised host, with intravenous acyclovir when oral intake is impossible. Foscarnet covers acyclovir-resistant HSV.
CMV esophagitis is recognized by one or more large, deep, often serpiginous ulcers in the distal esophagus, sometimes described as punched-out or geographic. The histologic fingerprint is owl-eye intranuclear inclusions and basophilic cytoplasmic inclusions in endothelial cells and stromal fibroblasts in the submucosal tissue. The biopsy site again matters. CMV biopsies are taken from the ulcer base, because that is where the infected stromal cells live. So hold the pairing: HSV is the epithelial-edge diagnosis, CMV is the stromal-base diagnosis. Forgetting the biopsy-site distinction is the place careful reading misses the organism. The host pattern that points toward CMV is HIV with CD4 under one hundred, solid-organ transplantation, or chemotherapy-induced neutropenia. Treatment is intravenous ganciclovir at five milligrams per kilogram twice daily for induction, with transition to oral valganciclovir for completion. Foscarnet is the alternative for ganciclovir-resistant disease. Chapter five carries the detailed infectious workup. That includes the decision rule for skipping empiric fluconazole and proceeding directly to EGD. The drivers are severity, immunocompromise, lack of fluconazole response, or a presentation that fits a viral or pill etiology rather than Candida.
So the through-line of this episode is that the diagnosis is recognized on the history, and the test confirms what the history already said. PPI failure in a patient who looks like GERD on the surface is the alert that the diagnosis is not GERD. Globus is reassured. Rumination is retrained with diaphragmatic breathing. Functional chest pain is neuromodulated. Functional heartburn and reflux hypersensitivity are sorted by their acid-exposure profile in chapter three. And odynophagia is sorted by the pill axis, the immune-status axis, and the prior-injury axis before a scope is ordered, with the biopsy site separating HSV from CMV.
That leaves the dysphagias that the standard workup misses because the diagnosis lives outside the EGD report. Episode three takes those on. The post-surgical dysphagias after fundoplication and bariatric surgery, read first on a barium swallow that shows the geometry. And the systemic dysphagias recognized by the disease outside the GI tract, with the manometric fingerprint of scleroderma as the one to carry forward.